We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

46 hedge funds and large institutions have $284M invested in Aclaris Therapeutics in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 2

380% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 5

35% more funds holding

Funds holding: 34 → 46 (+12)

3% more capital invested

Capital invested by funds: $276M → $284M (+$7.68M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
46
Holders Change
+12
Holders Change %
+35.29%
% of All Funds
1.23%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
14
Increased
24
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Fidelity International
Fidelity International
Bermuda
+$14.8M
2
CAM
Cormorant Asset Management
Massachusetts
+$5.02M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$4.95M
4
RSCM
Rock Springs Capital Management
Maryland
+$2.07M
5
BFA
BlackRock Fund Advisors
California
+$1.74M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$20.1M
2
TI
Turner Investments
Pennsylvania
-$1.65M
3
Franklin Resources
Franklin Resources
California
-$1.28M
4
OM
Opaleye Management
Massachusetts
-$341K
5
Citigroup
Citigroup
New York
-$149K
Name Holding Trade Value Shares
Change 		Change in
Stake
EEG
26
E.E. Geduld
$323K +$133K +6,729 +62%
SM
27
Sabby Management
Florida
$292K +$313K +15,812 New
Swiss National Bank
28
Swiss National Bank
Switzerland
$283K +$303K +15,300 New
TA
29
Teachers Advisors
New York
$262K +$134K +6,772 +91%
New York State Common Retirement Fund
30
New York State Common Retirement Fund
New York
$210K +$176K +8,900 +363%
TAM
31
Tocqueville Asset Management
New York
$185K +$198K +10,000 New
Manulife (Manufacturers Life Insurance)
32
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$139K +$67.6K +3,410 +83%
NFA
33
Nationwide Fund Advisors
Ohio
$106K +$36.4K +1,838 +47%
AIG
34
American International Group
New York
$95.8K +$37K +1,867 +56%
SO
35
STRS Ohio
Ohio
$55K +$21.8K +1,100 +58%
BA
36
BlackRock Advisors
Delaware
$53K +$18.4K +927 +48%
Legal & General Group
37
Legal & General Group
United Kingdom
$31K +$32.5K +1,638 New
Wells Fargo
38
Wells Fargo
California
$30K -$4.14K -209 -11%
Teacher Retirement System of Texas
39
Teacher Retirement System of Texas
Texas
$29K +$30.7K +1,548 New
Canada Life
40
Canada Life
Manitoba, Canada
$22K +$23.8K +1,200 New
Citigroup
41
Citigroup
New York
$18K -$149K -7,509 -88%
UBS Group
42
UBS Group
Switzerland
$17K +$6.1K +308 +49%
BlackRock
43
BlackRock
New York
$16K +$9.91K +500 +143%
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$6.41K +$6.88K +347 New
Bank of America
45
Bank of America
North Carolina
$3K +$3.37K +170 New
TRCT
46
Tower Research Capital (TRC)
New York
$2K -$1.7K -86 -46%
Morgan Stanley
47
Morgan Stanley
New York
$2K +$2.26K +114 New
TI
48
Turner Investments
Pennsylvania
– -$1.65M -87,004 Closed
OM
49
Opaleye Management
Massachusetts
– -$341K -18,000 Closed
1
2

ACRS Hedge Fund Activity: Q2 2016 in Review

46 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2016, worth a combined $284M — up 2.8% from $276M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ACRS positions and 2 closed out — a net gain of 12 holders — while 24 added to existing stakes and 5 trimmed.

The largest buyer was Fidelity International, opening a new position worth an estimated $14.8M. The largest seller was Fidelity Investments, cutting an estimated $20.1M.

  • 46 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2016, up from 34 in Q1 2016.
  • Funds reported $284M of Aclaris Therapeutics stock for Q2 2016, up 2.8% quarter-over-quarter.
  • 14 funds opened new Aclaris Therapeutics positions in Q2 2016 and 2 closed out, a net change of +12 holders.
  • The largest Aclaris Therapeutics buyer in Q2 2016 was Fidelity International, an estimated $14.8M added.
  • The largest Aclaris Therapeutics seller in Q2 2016 was Fidelity Investments, an estimated $20.1M sold.

Based on aggregated 13F filings for Q2 2016.